Rushikesh Sable
YOU?
Author Swipe
View article: Suppl Fig 6 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206<sup>high</sup> Macrophages Improve Antitumor Activity
Suppl Fig 6 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206<sup>high</sup> Macrophages Improve Antitumor Activity Open
Suppl Fig 6
View article: Suppl Fig 4 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206<sup>high</sup> Macrophages Improve Antitumor Activity
Suppl Fig 4 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206<sup>high</sup> Macrophages Improve Antitumor Activity Open
Suppl Fig 4
View article: Suppl Fig 1 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206<sup>high</sup> Macrophages Improve Antitumor Activity
Suppl Fig 1 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206<sup>high</sup> Macrophages Improve Antitumor Activity Open
Suppl Fig 1
View article: Supplementary Table S2 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206<sup>high</sup> Macrophages Improve Antitumor Activity
Supplementary Table S2 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206<sup>high</sup> Macrophages Improve Antitumor Activity Open
Cytotoxicity study of peptide analogs
View article: Supplementary Table S3 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206<sup>high</sup> Macrophages Improve Antitumor Activity
Supplementary Table S3 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206<sup>high</sup> Macrophages Improve Antitumor Activity Open
Supplementary Data_Drug Curves
View article: Suppl Fig 5 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206<sup>high</sup> Macrophages Improve Antitumor Activity
Suppl Fig 5 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206<sup>high</sup> Macrophages Improve Antitumor Activity Open
Suppl Fig 5
View article: Supplementary Table S1 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206<sup>high</sup> Macrophages Improve Antitumor Activity
Supplementary Table S1 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206<sup>high</sup> Macrophages Improve Antitumor Activity Open
Analytical data of investigated peptide analogues
View article: Data from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206<sup>high</sup> Macrophages Improve Antitumor Activity
Data from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206<sup>high</sup> Macrophages Improve Antitumor Activity Open
As tumor-associated macrophages (TAM) exercise a plethora of protumor and immune evasive functions, novel strategies targeting TAMs to inhibit tumor progression have emerged within the current arena of cancer immunotherapy. Activation of t…
View article: Suppl Fig 2 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206<sup>high</sup> Macrophages Improve Antitumor Activity
Suppl Fig 2 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206<sup>high</sup> Macrophages Improve Antitumor Activity Open
Suppl Fig 2
View article: Suppl Fig 3 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206<sup>high</sup> Macrophages Improve Antitumor Activity
Suppl Fig 3 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206<sup>high</sup> Macrophages Improve Antitumor Activity Open
Suppl Fig 3
View article: Suppl Fig 7 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206<sup>high</sup> Macrophages Improve Antitumor Activity
Suppl Fig 7 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206<sup>high</sup> Macrophages Improve Antitumor Activity Open
Suppl Fig 7
View article: Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206high Macrophages Improve Antitumor Activity
Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206high Macrophages Improve Antitumor Activity Open
As tumor-associated macrophages (TAM) exercise a plethora of protumor and immune evasive functions, novel strategies targeting TAMs to inhibit tumor progression have emerged within the current arena of cancer immunotherapy. Activation of t…
View article: Data from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Data from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling Open
Combinatorial molecular therapy in pancreatic ductal adenocarcinoma (PDAC) has yielded largely disappointing results in clinical testing to-date as a multitude of adaptive resistance mechanisms is making selection of patients via molecular…
View article: Figure S7 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Figure S7 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling Open
Schematic layout of the selumetinib versus 26 compounds targeting effector signaling of CNKSR1 screen; and Dose response of MK-2206 and rapamycin in the pancreas cancer cell lines.
View article: Figure S3 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Figure S3 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling Open
Dose response of PK-59 cells transfected with scramble siRNA and indicated candidate gene siRNAs; and CNKSR1 immunohistochemical staining in pancreas cancer tissues.
View article: Figure S6 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Figure S6 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling Open
MEK blockade fails to disrupt protein-protein interactions of CNKSR1, KSR1/2, and MEK in CNKSR1low cancer cells.
View article: Figure S1 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Figure S1 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling Open
Resistance to MEK inhibition in YAPC cells is not due to reactivation of phospho-Extracellular-signal-regulated-kinases (ERK) levels.
View article: Figure S7 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Figure S7 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling Open
Schematic layout of the selumetinib versus 26 compounds targeting effector signaling of CNKSR1 screen; and Dose response of MK-2206 and rapamycin in the pancreas cancer cell lines.
View article: Figure S4 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Figure S4 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling Open
CNKSR1 promotes MEK inhibition-induced AKT activation.
View article: Figure S4 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Figure S4 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling Open
CNKSR1 promotes MEK inhibition-induced AKT activation.
View article: Figure S5 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Figure S5 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling Open
Selumetinib fails to recruit CNKSR1 and p-AKT to the plasma membrane in CNKSR1 low cell lines; Proximal ligation of CNKSR1 and p-AKT in CNKSR1 low cell lines treated with vehicle vs selumetinib;CNKSR1 p-AKT PLA signal after treatment with …
View article: Figure S2 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Figure S2 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling Open
Secondary validation of candidate genes.
View article: Figure S2 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Figure S2 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling Open
Secondary validation of candidate genes.
View article: Table S1 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Table S1 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling Open
Lists of cell lines, antibodies, RNAi kinome screen; and matrix drug combination.
View article: Figure S1 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Figure S1 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling Open
Resistance to MEK inhibition in YAPC cells is not due to reactivation of phospho-Extracellular-signal-regulated-kinases (ERK) levels.
View article: Figure S6 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Figure S6 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling Open
MEK blockade fails to disrupt protein-protein interactions of CNKSR1, KSR1/2, and MEK in CNKSR1low cancer cells.
View article: Figure S5 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Figure S5 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling Open
Selumetinib fails to recruit CNKSR1 and p-AKT to the plasma membrane in CNKSR1 low cell lines; Proximal ligation of CNKSR1 and p-AKT in CNKSR1 low cell lines treated with vehicle vs selumetinib;CNKSR1 p-AKT PLA signal after treatment with …
View article: Figure S3 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Figure S3 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling Open
Dose response of PK-59 cells transfected with scramble siRNA and indicated candidate gene siRNAs; and CNKSR1 immunohistochemical staining in pancreas cancer tissues.
View article: Table S1 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Table S1 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling Open
Lists of cell lines, antibodies, RNAi kinome screen; and matrix drug combination.
View article: Figure S3 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Figure S3 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling Open
Dose response of PK-59 cells transfected with scramble siRNA and indicated candidate gene siRNAs; and CNKSR1 immunohistochemical staining in pancreas cancer tissues.